Drugs / ABD-3001
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05601726 | Nov 2022 → Jun 2026 overdue | acute myeloid leukemia, myelodysplastic syndrome | Advanced BioDesign | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ABD-3001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05601726 ↗ |
| Action | Inhibit | “ABD-3001, a competitive and irreversible inhibitor of ALDHs 1 and 3” PMID 39392121 ↗ Oct 2024 |
| Route | Intravenous | “fixed 4 hours-intravenous infusion dose” NCT05601726 ↗ |